Workflow
Medtronic(MDT)
icon
Search documents
NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus
ZACKS· 2025-03-12 17:10
The medical device industry is undergoing a profound change in 2025, driven by advancements in generative AI and agentic AI. At the forefront of this revolution are players like NVIDIA (NVDA) , whose AI computing platforms are accelerating AI-powered medical applications and capturing investors’ attention.NVIDIA’s Clara platform, powered by generative AI, is enabling real-time medical imaging enhancements and predictive diagnostics. Additionally, NVIDIA’s BioNeMo, a generative AI model tailored for life sci ...
Handheld Multi-Parameter Monitoring Devices Market Size to Cross US$ 5.3 Billion by 2035, Growing at 4.6% CAGR with Rising Demand for Portable Diagnostics – Analysis by TMR
Globenewswire· 2025-03-11 15:53
Core Insights - The handheld multi-parameter monitoring devices market is experiencing significant growth driven by the demand for portable and real-time health monitoring solutions [2][3] - The market was valued at US$ 3.2 billion in 2024 and is projected to grow at a CAGR of 4.6%, reaching over US$ 5.3 billion by 2035 [2][3] Market Drivers - Increasing prevalence of chronic diseases such as cardiovascular diseases, diabetes, and respiratory disorders necessitates continuous monitoring [6] - The shift towards home healthcare and remote patient monitoring is fostering personalized and decentralized healthcare solutions [6] - Advancements in sensor and wearable technologies are leading to the development of lightweight, non-invasive, and AI-integrated monitoring systems [6] - The growing geriatric population demands easy-to-use, real-time health tracking solutions [6] - The integration of telemedicine and digital health is expanding the adoption of cloud-based and Bluetooth-enabled diagnostic tools [6] Competitive Landscape - Key players in the market include Abbott, Medtronic, Koninklijke Philips N.V., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., GE HealthCare, and NIHON KOHDEN CORPORATION [7][11] - Companies are focusing on investments in sensor technology, AI-based analytics, and wireless connectivity to enhance patient monitoring experiences [7] Market Segmentation - By application, the market share is distributed as follows: Hospital & Clinical Use (40%), Home Healthcare (30%), Emergency & Critical Care (20%), and Military & Remote Healthcare (10%) [13] - By region, North America holds 45% market share, followed by Europe at 30%, Asia-Pacific at 15%, and the Rest of the World at 10% [14] Future Outlook - Emerging opportunities include portable handheld monitors for hospitals and home care, wearable multi-parameter devices integrated with smart technology, and wireless devices enabling remote monitoring [15] - The market is characterized by rapid technological advancements and increasing investments in healthcare infrastructure [9][10]
Positive Trial Data on Evolut TAVR Likely to Support MDT Stock
ZACKS· 2025-03-10 13:40
Medtronic plc (MDT) recently unveiled two-year Small Annuli Randomized to Evolut or SAPIEN (“SMART”) Trial results at the Cardiovascular Research Technologies (“CRT”) 2025 conference in Washington, D.C. SMART trial is the largest international head-to-head comparative trial of transfemoral transcatheter aortic valve replacement ("TAVR"), conducted in patients with aortic stenosis ("AS") and a small aortic annulus. The two-year results highlighted the continued superior performance of the Evolut TAVR valve i ...
2025医学装备大会抢先看!38家企业大盘点:美敦力、赛诺威盛、精锋……
思宇MedTech· 2025-03-10 10:31
合作伙伴征集:2025全球手术机器人大会 报名:首届全球眼科大会 | 暂定议程 报名:首届全球心血管大会 | 奖项报名倒计时 报名:首届全球骨科大会 | 奖项报名倒计时 在医疗科技深度融合临床实践的当下,医学装备行业正经历技术与应用的双重跃迁。从精准诊断到微创治疗,从智能康复到个性化医疗,医学装备的每一次 技术突破都直接影响着医疗质量与患者预后。然而,行业的高速发展不仅带来了创新机遇,也伴随着标准化、适应性落地和成本控制等多重挑战。 在这一背景下, 2025中国医学装备大会暨医学装备展览会 成为观察行业动向的重要窗口。2025年3月13日至16日,重庆国际博览中心将汇聚 800多家企 业 ,展示超过 1000件创新产品 。这不仅是一场技术竞演,更是对医疗装备未来走向的深度探讨——哪些技术能够真正提升临床价值?国产创新如何突破市 场壁垒?政策与产业如何协同推动高质量发展?答案,或将在这次行业盛会上逐步揭晓。 # 会议信息 此次参会的龙头企业包括 强生、雅培、美敦力、直观复星、上海微创机器人、迈瑞医疗、东软医疗、GE医疗、西门子医疗、飞利浦、罗氏、碧迪医疗 等。 34大 专业展区,覆盖了从基础到前沿的每一个细分领 ...
SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patients
Prnewswire· 2025-03-09 18:00
Core Insights - The SMART Trial presents the two-year results of the largest international head-to-head randomized control trial comparing Evolut and SAPIEN TAVR devices, primarily enrolling women with small aortic annuli [1][3][4] - Evolut TAVR demonstrated superior valve performance and significantly less bioprosthetic valve dysfunction (BVD) compared to SAPIEN TAVR, which is critical for patients with small aortic annuli [2][4][6] Company Overview - Medtronic plc is a global leader in healthcare technology, headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [6] - The company employs over 95,000 people across 150 countries, focusing on innovative technologies that address challenging health problems [6][7] Industry Context - Aortic stenosis affects approximately 1.5 million people in the U.S., with a significant portion of the global market having small aortic annuli, necessitating tailored valve selection [5] - The SMART Trial's findings are expected to inform and personalize treatment decisions for patients with symptomatic severe aortic stenosis [2][4]
2 Dependable Dividend Stocks That Can Pay You for Life
The Motley Fool· 2025-03-07 13:15
Core Insights - High dividend yields can be attractive, but companies must have a reliable business model to avoid payout cuts [1] - Medtronic and Abbott Laboratories are highlighted as strong dividend stocks in the healthcare sector [2] Medtronic - Medtronic operates in various therapeutic areas, including diabetes care, neuroscience, cardiovascular health, and medical-surgical, with around 120 product approvals in the last year [3][4] - The company has a strong position in healthcare and innovative capabilities, contributing to consistent financial performance [4][6] - Medtronic has raised its dividends for 47 consecutive years, with a forward yield of 3%, significantly higher than the S&P 500 average of 1.3% [8] Abbott Laboratories - Abbott Laboratories has increased its dividends for 52 consecutive years, indicating strong financial health and operational diversity [9] - The company has a diversified business model, including pharmaceuticals, diagnostics, and nutrition, which helps mitigate risks in its medical device segment [9][10] - Abbott's FreeStyle Libre is a leading continuous glucose monitoring system, with significant growth potential as only 1% of adults globally have access to CGM technology [10][11] - The forward yield for Abbott is 1.7%, supported by a strong underlying business and growth prospects [14]
Medtronic announces cash dividend for fourth quarter of fiscal year 2025
Prnewswire· 2025-03-06 21:30
Core Points - Medtronic plc's board of directors approved a cash dividend of $0.70 per ordinary share for the fourth quarter of fiscal year 2025, consistent with a previous dividend increase announced in May 2024 [1] - Medtronic has a strong history of dividend payments, having increased its annual dividend for 47 consecutive years, and is part of the S&P 500 Dividend Aristocrats index [1] - The dividend will be payable on April 11, 2025, to shareholders of record as of March 28, 2025 [1] Company Overview - Medtronic, headquartered in Galway, Ireland, is a leading global healthcare technology company focused on addressing significant health challenges through innovative solutions [2] - The company's mission is to alleviate pain, restore health, and extend life, supported by a global workforce of over 95,000 employees across more than 150 countries [2] - Medtronic's technologies and therapies address 70 health conditions, including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems [2]
Medtronic(MDT) - 2025 Q3 - Quarterly Report
2025-02-25 21:17
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Commission File Number 001-36820 (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State of incorporation) (I.R.S. Employer Identification No.) Building Two, Parkmore Business Park West Galway, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | ...
Distributor Purchasing Shifts Mar MDT's Q3 Show: How to Play the Stock
ZACKS· 2025-02-24 18:15
Core Viewpoint - Medtronic's mixed performance in Q3 fiscal 2025 led to a stock decline of over 7% due to revenue falling short of estimates, primarily impacted by a decline in medical-surgical unit sales [1][12]. Financial Performance - Q3 revenues were reported at $8.29 billion, slightly below the Zacks Consensus Estimate of $8.33 billion [1]. - The Diabetes segment grew by 8.4%, driven by strong demand for insulin delivery systems [2]. - Neuromodulation showed above-market performance, particularly in Pain Stim growth, with strong U.S. growth from the Inceptiv spinal cord stimulator launch [2]. - Year-to-date, the stock has gained 12.5%, outperforming the broader industry and sector [3]. Market Trends - Analysts have shown cautious optimism with mixed estimate revisions for fiscal 2025, with earnings estimates improving slightly to $5.46 per share [6]. - Medtronic's Q3 performance included a 22% surge in Cardiac Ablation Solutions and double-digit growth in leadless pacing and diabetes [8]. - The company expects revenue and EPS growth to accelerate in Q4, supported by its innovation pipeline and market expansion [10]. Competitive Position - Medtronic's stock is trading at a forward P/E of 15.60X, lower than the industry average of 22.58X, indicating a potentially attractive valuation [11]. - Key challenges include disruptions in the Medical Surgical segment due to shifts in U.S. distributor buying patterns, which impacted revenues by approximately 200 basis points [12]. - The company is facing competitive pressures in the stapling business but has seen growth in LigaSure Advanced Energy Products [13]. Operational Efficiency - Medtronic's trailing 12-month return on equity (ROE) is 14.07%, below the industry average of 16.71%, indicating less effective utilization of equity capital [15].
Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's
Prnewswire· 2025-02-24 14:00
Core Viewpoint - Medtronic has received FDA approval for its BrainSense™ Adaptive deep brain stimulation (aDBS) technology, marking a significant advancement in personalized treatment for Parkinson's disease, which affects approximately one million people in the U.S. [1][9] Group 1: Product Innovation - The aDBS technology personalizes therapy based on real-time brain activity, enhancing symptom control and reducing the need for manual adjustments by patients [3][4] - Medtronic's BrainSense™ Electrode Identifier (EI) allows for faster and more accurate programming of DBS settings, improving efficiency by 85% compared to traditional methods [7][8] Group 2: Clinical Impact - The ADAPT-PD trial, led by prominent neurologists, demonstrated the safety and effectiveness of aDBS compared to continuous DBS, representing the largest assessment of its kind [5][6] - The adaptive nature of aDBS is expected to significantly improve symptom control for patients experiencing motor fluctuations and dyskinesias [6][7] Group 3: Market Position - Medtronic is the only company offering a real-time adaptive DBS system, positioning itself as a leader in integrating brain-computer interface technology into therapeutic solutions for neurological disorders [4][9] - With over 40,000 DBS patients served globally, the launch of BrainSense™ Adaptive DBS is the largest commercial rollout of BCI technology to date [4][9]